Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Albuterol

Criteria

Inclusion Criteria:

• Patient greater than or equal to 18 years of age,

• non-smokers,

• diagnosed with asthma, with an FEV1 less than or equal to 70 percent of predicted normal,

• stable use of Beta agonist

• daily use of inhaled steroids for one year

Exclusion Criteria:

• Patients with other significant diseases other than asthma, requiring oxygen,

• intubated within 5 years,

• asthma exacerbation within 6 weeks of trial,

• use of unstable doses (greater than 10 mg/day of prednisone or equivalent) of steroids,

• participating in another interventional trial